Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Ginkgo Bioworks (NYSE: DNA) has announced its participation in the Jefferies Virtual Synthetic Biology Week, scheduled for March 22, 2022, at 10:00 a.m. Eastern Time. Management will engage in a fireside chat during this event. Details, including a webcast link and a replay, will be available on the company's investor relations website. Ginkgo operates a platform for cell programming, supporting various biotechnology applications across markets like food, agriculture, and pharmaceuticals, while also contributing to COVID-19 response efforts.
Ginkgo Bioworks (NYSE: DNA) has announced a definitive agreement to acquire FGen AG, a Swiss company specializing in strain development and ultra-high-throughput screening technology. This acquisition aims to enhance Ginkgo's cell screening capabilities, allowing exploration of a broader genetic opportunity space. Ginkgo expects that integrating FGen's technology will significantly improve their Design-Build-Test-Learn engine, increasing throughput and efficiency in analyzing millions of genetic prototypes. The transaction is expected to close promptly, with FGen receiving upfront payment and contingent considerations.
Ginkgo Bioworks (NYSE: DNA) announced its participation in notable upcoming conferences, enhancing its visibility in the biotech sector. The events include the Truist Securities AI Symposium on March 1, 2022, Cowen 42nd Annual Health Care Conference on March 8, 2022, featuring a fireside chat and a panel discussion, and the HSBC Build with Bio Conference on March 10, 2022. Interested parties can find more information, webcast links, and presentation replays on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) announced its participation in two upcoming conferences. The BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference is scheduled for February 15, 2022, at 10:00 a.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference will take place on February 18, 2022, at 10:40 a.m. ET. Interested parties can find more details and webcast links on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has acquired Project Beacon COVID-19 LLC, a Boston-based organization focused on enhancing COVID-19 testing accessibility and affordability. This acquisition aims to integrate Project Beacon's assets with Ginkgo's Concentric platform, increasing testing capabilities in Massachusetts and surrounding areas. Ginkgo's Concentric currently serves over 280,000 individuals weekly, having conducted over 3 million tests in the latter half of 2021. The merger is expected to bolster community health initiatives amid rising pandemic concerns.
Ginkgo Bioworks (NYSE: DNA) announced preliminary performance updates for the year ending December 31, 2021. The company expects to meet or exceed its 2021 targets with Biosecurity revenue surpassing its outlook by over 50%. Key highlights include the addition of 30 new cell programs and Foundry revenue exceeding $100 million. Ginkgo reported significant testing volumes through its public health initiative, Concentric, which collected over 280,000 samples weekly. The company will provide audited financial results in March 2022, alongside its outlook for 2022.
Inscripta has announced that Ginkgo Bioworks (NYSE: DNA) has integrated its Onyx™ genome engineering platform into its foundries. This partnership aims to enhance Ginkgo's metabolic and protein engineering workflow efficiency. Initial evaluations indicate that Onyx improved genome editing throughput significantly and reduced design-build-test-learn cycle times by at least 50%. Ginkgo plans to continue investing in innovative technologies that provide faster product development and increased performance in its offerings.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) announced a collaboration on January 10, 2022, to develop next-generation viral capsids for gene therapy. This partnership combines Selecta's ImmTOR platform with Ginkgo's cell programming technology to enhance transduction, tissue tropism, and reduce immunogenicity. Ginkgo will engineer the capsids, while Selecta handles pre-clinical and clinical studies. Financially, Ginkgo could receive up to $1.1 billion in total payments, including milestone payments in Selecta stock and royalties.
Optimvia has partnered with Ginkgo Bioworks (NYSE: DNA) to enhance the manufacturing efficiency of biosynthetic heparin, a critical medicine traditionally sourced from industrial animal agriculture. This collaboration aims to utilize Ginkgo's expertise in cell and enzyme engineering to improve Optimvia's production technology. The initiative seeks to develop non-animal-derived heparin, potentially reducing reliance on animal sources and increasing supply chain resilience for this essential drug.
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 p.m. Eastern Time. The presentation details, along with a webcast link and replay information, will be available on the company's investor relations website. Ginkgo Bioworks focuses on programming cells for various biotechnology applications, supporting efforts such as COVID-19 testing and vaccine optimization.
